Chronic Kidney Failure

A recent analysis found that factors like age, BMI and diabetes status did not significantly affect improvements in sexual function or quality of life for men receiving testosterone replacement therapy.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, may improve CV risk among patients with type 2 diabetes and kidney disease and those with albuminuria, according to a FIDELITY substudy published in JAMA Cardiology.

We are more than 1 year into the Medicare Kidney Care Choices model directed at patients with chronic kidney disease stages 4-5 and with end-stage kidney disease, a true test of value-based medicine.

Researchers found the National Kidney Foundation Patient Network feasible as a national registry to “inform the development of patient-centered research, care and treatments,” according to published findings.

The Organ Procurement and Transplant Network Board of Directors has unanimously voted to remove the race coefficient from eGFR equations.

Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed no certain impact on kidney function.

Compared with living donors aged 50 to 70 years, donor age older than 70 years may be a negative predictor of kidney transplant and graft survival, according to a presentation at the American Transplant Congress.

NEW ORLEANS — Tirzepatide, a novel glucose-lowering therapy, reduced urinary albumin secretion and slowed kidney function decline for adults with type 2 diabetes and high cardiovascular risk, according to data from the SURPASS-4 trial.

J. Kevin Tucker, MD, nephrologist and vice president for education at Mass General Brigham, was honored with the Donald W. Seldin Award from the National Kidney Foundation, according to a press release.

Patients with pulmonary hypertension who underwent kidney transplantation had similar posttransplant outcomes at 5 years compared with those without pretransplant pulmonary hypertension, researchers reported in Pulmonary Circulation.